Products
Tizetatug Biosimilar Monoclonal Antibody (TROP-2) for Research
Cat No.: GMP-Bios-INN-1420
Anti-TACSTD2/TROP2/EGP1 therapeutic antibody (Pre-made Tizetatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tizetatug (development code SHR-1921) is a humanized monoclonal antibody targeting TACSTD2, TROP2 and EGP1. It is developed by Atridia and Suzhou Suncadia Biopharmaceuticals for Ovarian cancer, Salivary gland cancer, Solid tumours in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1420-1mg | 1mg | 3090 |
| GMP-Bios-INN-1420-10mg | 10mg | |
| GMP-Bios-INN-1420-100mg | 100mg | |
| GMP-Bios-INN-1420-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tizetatug biosimilar, Whole mAb, Anti-TACSTD2/TROP2/EGP1 Antibody: Anti-TACSTD2/TROP2/Tumor-associated calcium signal transducer 2/Cell surface glycoprotein Trop-2 therapeutic antibody |
| INN Name | Tizetatug |
| Target | TACSTD2/TROP2/EGP1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Atridia;Suzhou Suncadia Biopharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Ovarian cancer;Salivary gland cancer;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
